Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

AIC. Dynavax.

Barbara Bohle1

  • 1Department of Pathophysiology, Division of Immunopathology, University of Vienna, AKH-EBO 3Q, Wahringer Gurtel 18-20, 1090 Vienna, Austria. barbara.bohle@akh-wien.ac.at

Current Opinion in Investigational Drugs (London, England : 2000)
|July 2, 2003
PubMed
Summary

Dynavax is developing Amb a 1 immunostimulatory oligodeoxynucleotide-conjugate (AIC) for ragweed allergies. Clinical trials were progressing in North America and Europe, with a Phase III trial anticipated in 2003.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Preventive Application of House Dust Mite-Sublingual Immunotherapy Induces Blocking Antibodies in Sensitized Preschool Children.

Allergy·2026
Same author

Complexes of allergen and specific IgG antibodies activate human neutrophils.

Frontiers in allergy·2026
Same author

Allergic Sensitization to Inhalant Allergens in the Upper Respiratory Tract-the B Cell Side.

Allergy·2026
Same author

Identification of an immunodominant IgE epitope on Mal d 1 and its role for treatment of birch pollen-related apple allergy.

Allergology international : official journal of the Japanese Society of Allergology·2025
Same author

Structured Fresh Apple Consumption for Birch Pollen Food Allergy Syndrome in an Uncontrolled Phase II/III Trial.

The journal of allergy and clinical immunology. In practice·2025
Same author

Cross-protection of allergen immunotherapy-induced antibodies to related allergens requires a high degree of structural identity.

Allergy·2024

Area of Science:

  • Immunotherapy
  • Allergy Research
  • Vaccine Development

Background:

  • Seasonal allergies, such as those induced by ragweed, affect a significant portion of the population.
  • Current treatments for ragweed allergy primarily focus on symptom management.
  • There is a need for disease-modifying immunotherapies.

Purpose of the Study:

  • To evaluate the safety and efficacy of Amb a 1 immunostimulatory oligodeoxynucleotide-conjugate (AIC) as a novel immunotherapy for ragweed-induced seasonal allergy.
  • To advance the development of AIC through clinical trials.

Main Methods:

  • Amb a 1 immunostimulatory oligodeoxynucleotide-conjugate (AIC) is a novel therapeutic conjugate under development.
  • Clinical trials, including Phase II and Phase III, were conducted in multiple countries.

Main Results:

  • Phase II/III trials were initiated in Canada and the US by May 2001.
  • Phase II trials commenced in France by March 2002.
  • A Phase III trial was planned for commencement in 2003.

Conclusions:

  • The development of AIC as a potential immunotherapy for ragweed allergy was progressing through clinical evaluation.
  • The ongoing trials indicated a commitment to advancing this novel therapeutic approach.

Related Experiment Videos